Replimune Group, Inc. (REPL) Form 424B5 — Aug 10, 2026
Replimune Group priced a $150.0 million underwritten offering of 9,701,490 common shares at $12.06 per share, plus pre-funded warrants for 2,736,340 shares at $12.0599, for estimated net proceeds of approximately $140.5 million. Closing is expected on or about August 11, 2026, with Leerink Partners, J.P. Morgan and Cantor as bookrunning managers and a 45-day lock-up on the company and insiders. The raise comes days after the FDA granted accelerated approval of TUDRIQEV (vusolimogene oderparepvec-wtpg, formerly RP1) with nivolumab for adults with unresectable advanced cutaneous melanoma who progressed on anti-PD-1 therapy.
Key figures
- Net Income
- -$313.9 million net loss for fiscal year ended March 31, 2026 (vs. $247.3 million loss in FY2025)
- Cash Position
- 268900000
- Gross Proceeds
- 149999956
- Offering Price
- 12.06
- Shares Offered
- 9,701,490 shares of common stock plus pre-funded warrants to purchase 2,736,340 shares
- Shares Outstanding
- 92,418,413 shares outstanding after the offering (82,716,923 as of March 31, 2026)
- Prior CRLs
- 2
- Lockup Days
- 45
- Atm Capacity
- 100000000
- Authorized Shares
- 150,000,000 currently; proposed increase to 300,000,000 at September 15, 2026 annual meeting; 30,258,728 remained available as of March 31, 2026
- Ignyte3 Trial Size
- approximately 400 patients, FDA postmarketing requirement / confirmatory study
- Net Proceeds Estimate
- approximately $140.5 million
- Advisory Committee Vote
- 10 to 3 in favor of IGNYTE being evaluable and clinically meaningful (July 30, 2026)
- Prefunded Warrant Price
- 12.0599
- Underwriting Discounts
- 9000014
- Proceeds Before Expenses
- 140999942
- Ignyte Melanoma Cohort ORR
- 24.2% with median duration of response of 14.1 months (91 efficacy-evaluable patients)
- Estimated Offering Expenses
- approximately $450,000 plus $45,000 FINRA counsel reimbursement
- Prefunded Warrant Exercise Price
- 0.0001
- Last Reported Sale Price Aug7 2026
- 12.06
- Dilution Percent Including Warrant Shares
- approximately 15.0% (12,437,830 new shares vs. 82,716,923 outstanding)
- Immediate Dilution Per Share New Investors
- 9.18
- As Adjusted Net Tangible Book Value Per Share
- 2.88
- Net Tangible Book Value Per Share Pre Offering
- 1.72
Price after filing
Close on the filing date to close N calendar days later (from $12.06). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.